Jason Milovanovic has over 20 years of experience in clinical drug development. As a cross-functional team leader, he has managed numerous clinical development teams at both, the study operational and strategic program level, for compounds across development life cycles (i.e., from first in human through registration, as well as post-marketing study commitments and life cycle management/alternative indications). Therapeutic indications have included acute coronary syndrome, pulmonary hypertension, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, REM-based sleep disorder, migraine, major depressive disorder, asthma, oncology, ototoxicity, dermatomyositis, glaucoma, allergic conjunctivitis, rheumatoid arthritis, schizophrenia, diabetes, and obesity. He also has extensive experience evaluating, selecting, and managing CROs across therapeutic areas and phases of development.

Before joining Halloran, Jason was a project director in the Early Product Development group at PAREXEL where he oversaw the delivery of clinical studies. Before that, Jason held positions of increasing responsibility within Global Clinical Operations at Biogen. This included serving as the Clinical Development team leader for several compounds, director of the Early Phase Clinical Operations group, and most recently, director of the Vendor Relationship Management team where he held accountability for successful implementation and governance of a companywide strategic CRO partnership. Jason has also held positions at Alkermes, Millennium, and Predix as well as ophthalmology based CRO, ORA. Jason started his biotech career in a clinical setting as a respiratory therapist.